Short description
Stemline Therapeutics is a clinical stage biopharmaceutical company developing oncology compounds that target cancer stem cells.
Description
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company and a leading developer of novel oncology compounds directed to cancer stem cell targets. Stemline’s lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human trial.
Behind its lead, Stemline is developing a broad portfolio of compounds directed at this and other high value cancer stem cell targets of a variety of hematological and solid cancers. In addition, Stemline has built a robust discovery platform called “StemScreen®†which the Company has utilized to identify multiple compounds that target and impair cancer stem cells.
Stemline also possesses a comprehensive intellectual property portfolio that includes the earliest filings in the cancer stem cell field covering cancer stem cell-directed therapeutics, diagnostics, and drug screening.
Last funding
Noaccessforu
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
New York, New York, United States, North America
Founded on
August 1, 2003
Exited on
January 29, 2013
Went public on
January 29, 2013
Stock symbol
STML
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$56378 - 90123
Sign in for full access
Investors
Nopepepe
Sign in for full access
Founders
Ivan Bergstein